期刊文献+

Anti-anxiety effect of Valeriana jatamansi Jones extract via regulation of the hypothalamus-pituitary-adrenal axis 被引量:9

Anti-anxiety effect of Valeriana jatamansi Jones extract via regulation of the hypothalamus-pituitary-adrenal axis
下载PDF
导出
摘要 BACKGROUND: Hypothalamus-pituitary-adrenal (HPA) axis dysfunction has been closely linked to anxiety. Previous studies have shown that Valeriana jatamansi Jones extract exhibits clear anxiolytic effects, but it is unclear about the mechanism underlying regulation of the HPA axis dysfunction in these anxiolytic effects. OBJECTIVE: To observe the effects of Valeriana jatamansi Jones (Zhizhu Xiang) extract on HPA axis function in a rat model of anxiety, and to compare these effects with positive control estazolam. DESIGN, TIME AND SETTING: Randomized, controlled, animal experiment was performed at Chengdu University of Traditional Chinese Medicine, China, between February and September in 2006. MATERIALS: Estazolam was purchased from Shanghai Jiufu Pharmaceutical, China; Valeriana jatamansiJones was purchased from the Lotus Pond Market for Chinese Herbal Medicine in Chengdu. It consisted of iridoids and flavonoid components. METHODS: A total of 72 Sprague Dawley rats, aged 2 months, were randomly assigned to 6 groups low-, medium-, and high-dose Valerianajatamansi Jones groups intragastrically injected with 0.3, 0.6, and 0.9 g/kg per day Valerianajatamansi Jones extract, respectively; estazolam group intragastrically injected with 1.5 mg/kg per day estazolam; model and normal groups administered 5 mL physiological saline. Anxiety was established in all groups, except the normal group, through the use of elevated plus-maze test at 7 days following drug administration. MAIN OUTCOME MEASURES: Blood β-endorphin and corticosterone levels were determined using enzyme-linked immunosorbent assay following treatment with ValerianajatamansiJones extract. Expressions of HPA axis-related genes were measured by cDNA microarray. RESULTS: Blood β-endorphin and corticosterone levels were significantly greater in the model group than in the normal group. Compared with the model group, levels decreased with Valeriana jatamansi Jones extract or estazolam treatment, particularly in the low-dose Valeriana jatamansi Jones group (P〈 0.01). cDNA microarray results demonstrated that corticotropin-releasing hormone and Orexin, which are associated with HPA axis function, were differentially expressed; expression increased in the model group, but decreased in rats treated with Valerianajatamansi Jones extract. CONCLUSION: Valerianajatamansi Jones extract plays a role in regulating HPA axis function in a rat model of anxiety, and this effect was superior to estazolam. BACKGROUND: Hypothalamus-pituitary-adrenal (HPA) axis dysfunction has been closely linked to anxiety. Previous studies have shown that Valeriana jatamansi Jones extract exhibits clear anxiolytic effects, but it is unclear about the mechanism underlying regulation of the HPA axis dysfunction in these anxiolytic effects. OBJECTIVE: To observe the effects of Valeriana jatamansi Jones (Zhizhu Xiang) extract on HPA axis function in a rat model of anxiety, and to compare these effects with positive control estazolam. DESIGN, TIME AND SETTING: Randomized, controlled, animal experiment was performed at Chengdu University of Traditional Chinese Medicine, China, between February and September in 2006. MATERIALS: Estazolam was purchased from Shanghai Jiufu Pharmaceutical, China; Valeriana jatamansiJones was purchased from the Lotus Pond Market for Chinese Herbal Medicine in Chengdu. It consisted of iridoids and flavonoid components. METHODS: A total of 72 Sprague Dawley rats, aged 2 months, were randomly assigned to 6 groups low-, medium-, and high-dose Valerianajatamansi Jones groups intragastrically injected with 0.3, 0.6, and 0.9 g/kg per day Valerianajatamansi Jones extract, respectively; estazolam group intragastrically injected with 1.5 mg/kg per day estazolam; model and normal groups administered 5 mL physiological saline. Anxiety was established in all groups, except the normal group, through the use of elevated plus-maze test at 7 days following drug administration. MAIN OUTCOME MEASURES: Blood β-endorphin and corticosterone levels were determined using enzyme-linked immunosorbent assay following treatment with ValerianajatamansiJones extract. Expressions of HPA axis-related genes were measured by cDNA microarray. RESULTS: Blood β-endorphin and corticosterone levels were significantly greater in the model group than in the normal group. Compared with the model group, levels decreased with Valeriana jatamansi Jones extract or estazolam treatment, particularly in the low-dose Valeriana jatamansi Jones group (P〈 0.01). cDNA microarray results demonstrated that corticotropin-releasing hormone and Orexin, which are associated with HPA axis function, were differentially expressed; expression increased in the model group, but decreased in rats treated with Valerianajatamansi Jones extract. CONCLUSION: Valerianajatamansi Jones extract plays a role in regulating HPA axis function in a rat model of anxiety, and this effect was superior to estazolam.
出处 《Neural Regeneration Research》 SCIE CAS CSCD 2010年第14期1071-1075,共5页 中国神经再生研究(英文版)
基金 Project of Sichuan Provincial Traditional Chinese Medicine Administration,No.200674 Science Foundation of Southwest Jiaotong University,No.2006A10 "Key New Drug Innovation" National Science and Technology Major Projects During Eleventh Five-Year Plan,No.2009ZX09103-370 Chengdu Science and Technology Major Projects During Eleventh Five-Year Plan,No.09GGZD060SF-012
关键词 ANXIETY Valeriana jatamansi Jones hypothalamus-pituitary-adrenal axis RATS anxiety Valeriana jatamansi Jones hypothalamus-pituitary-adrenal axis rats
  • 相关文献

参考文献6

二级参考文献42

  • 1王代学,向正华,陈建新,宋田斌,刘淑琴,张俐,周洪堂.老年大鼠下丘脑β-内啡肽神经元的变化[J].老年学杂志,1993,13(1):49-50. 被引量:6
  • 2中华人民共和国卫生部药典委员会.中华人民共和国药典(一部)[M].北京:人民卫生出版社,1977.100.
  • 3Lesley A. Houghton. Evidence of abnormal rectal sensitivity in IBS. In:Michael Camilleri, Robin C Spiller. Irritable Bowel Syndrome: Diagnosis and Treatment, 2002.69-76.
  • 4Sykes MA, Blanchard EB, Lackner J, et al. Psychopathology in irritable bowel syndrome: support for a psychophysiological model. J Behav Med, 2003,26(4) :361-372.
  • 5Smulevich AB, Rappoport SI, Syrkin AL, et al. Visceral neuroses: clinical approaches to the problem. Zh Nevrol Psikhiatr Im S S Korsakova, 2002,102(1) :15-21.
  • 6Mayer EA, Naliboff BD, Chang L, et al. V. Stress and irrirable bowel syndrome. Am J Physiol Gastrointest Liver Physiol, 2001,280 (4) :G519-G524.
  • 7Sykes MA, Blanchard EB, Lackner J, et al. Psychopathology in irritable bowel syndrome:support for a psychophysiological model. J Behav Med, 2003,26(4) :361-372.
  • 8Greenwood-Van Meerveld B, Gibson M, Gunter W, et al. Stereotaxic delivery of corticosterone to the amygdala modulates colonic sensitivity in rats. Brain Res,2001,893(1-2): 135-142.
  • 9Gunter WD, Shepard JD, Foreman RD, et al. Evidence for visceral hypersensitivity in high-anxiety rats. Physiol Behav, 2000,69 (3): 379-382.
  • 10Lechner SM, Curtis AL, Brons R, et al. Locus coeruleus activation by colon distention: role of corticotropin-releasing factor and excitatory amino acids.Brain Res, 1997,756(1-2): 114-124.

共引文献95

同被引文献104

引证文献9

二级引证文献81

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部